Gonorrhea, which affects more than 80 million people worldwide each year, is a global threat to public health because of the increasing incidence of antimicrobial drug resistance, rising treatment costs and lack of a protective vaccine.
Former Georgia State cross country coach Nate Houle (M.S. ’15), with the help of his wife and former Panther runner Kacee (B.S. ’11), beat stage 4 carcinoma and got back on the track.
Congressman Hank Johnson recently visited Clarkston to hear how the Georgia State University Prevention Research Center is helping improve health and well-being.
Associate Professor Don Davis and colleagues received a $6 million grant from the John Templeton Foundation to better understand intellectual humility.
A new universal flu vaccine protects against influenza B viruses, offering broad defense against different strains and improved immune protection, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.
A new universal flu vaccine constructed with key parts of the influenza virus offers broad cross protection against different strains and subtypes of influenza A viruses, according to a new study by researchers in the Institute for Biomedical Sciences.
A new oral treatment for ulcerative colitis that focuses on reducing inflammation in gut microbiota has been developed by researchers in the Institute for Biomedical Sciences at Georgia State University, according to a new study.
An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase has been identified, a finding that could provide an effective treatment against RSV disease, according to researchers in the Center for Translational Antiviral Research at Georgia State University.
A nanoparticle vaccine that combines two proteins that induce immune responses against SARS-CoV-2, the virus that has caused the global pandemic, has the potential to be developed into broader and safe SARS-CoV-2 vaccines, according to researchers in the Institute for Biomedical Sciences at Georgia State University.
The new center at Emory and Georgia State is led and co-founded by researchers with a history of collaborating on successful antiviral drugs, including molnupiravir, which was one of the world’s first antiviral pills approved for use against SARS-CoV-2.
